The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global diabetes care devices market reached a value of US$ 27.11 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 44.01 Billion by 2027, exhibiting a CAGR of 8.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Diabetes care devices refer to equipment used to monitor or determine blood sugar levels. Smart insulin pens, glucometers, ketone, continuous glucose monitors (CGMs), insulin pumps and diabetes management applications are some of the common diabetes care devices. They consist of lancets, glucose sensors, monitors, docking stations, test plugs and test strips that help constantly monitor diabetic conditions. Diabetes care devices are widely used to diagnose and monitor diabetes mellitus, a chronic disorder that affects the amount of glucose absorption in the blood. Consequently, these devices assist in accurately identifying blood sugar levels, determining the effectiveness of diabetes treatment, and lowering the instances of hyperglycemia and hypoglycemia.
The growing prevalence of diabetes, especially amongst the steadily rising geriatric population across the globe, is creating a positive outlook for the market. Diabetes care devices are widely adopted to treat and manage symptoms and complications associated with the disorder, such as respiratory issues, kidney and liver failure, and cardiovascular conditions. In line with this, the extensive utilization of glucose monitoring and insulin delivery devices for better care and management of the disease is favoring the market growth. Apart from this, the introduction of smart diabetes devices integrated with artificial intelligence (AI), machine learning (ML) and the Internet of Things (IoT) to enable remote monitoring of the patient's symptoms and biomarkers are providing an impetus to the market growth. Additionally, the increasing demand for self-monitoring of blood glucose (SMBG) that includes information regarding the patient’s dynamic blood glucose profile is positively impacting the market growth. The reading further aids in the appropriate scheduling of food, activity, and medication, thus making them a valueable tool in the treatment of diabetes mellitus. Other factors, including extensive research and development (R&D) activities, evolving eating habits and sedentary lifestyles, and the implementation of various government initiatives focusing on providing better health services are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global diabetes care devices market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, distribution channel and end user.
Breakup by Type:
Breakup by Distribution Channel:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, ACON Laboratories Inc., Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation), Becton Dickinson and Company, Bionime Corporation, Dexcom Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Medtronic plc, Novo Nordisk A/S, Sinocare Inc. and Terumo Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Distribution Channel, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, ACON Laboratories Inc., Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation), Becton Dickinson and Company, Bionime Corporation, Dexcom Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Medtronic plc, Novo Nordisk A/S, Sinocare Inc. and Terumo Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at